Overview
Consano Bio is a biotechnology company developing a first-in-class therapeutic designed to target the underlying disease associated with painful and debilitating orthopedic conditions. The company’s wholly owned lead product, C-1101, is an Allogenic Multi-Protein Therapeutic (AMPT). Consano Bio is focused on advancing C-1101 toward clinical development milestones in chronic Lumbosacral Radiculopathy (LSR) and expanding our portfolio.